XBiotech Sinks To A New Low After The EMA Rejects Lead Drug

You can file this story in the Not Surprised folder.

Austin-based XBiotech’s application to start selling its lead cancer therapy has been spurned by European regulators.

That couldn’t have been completely unexpected as their lead drug — Xilonix — had offered up some dubious data. Investigators reported that the Phase III was marred by a mixup in treating the placebo and drug arms, a number of dropouts and improper patient evaluations.

Back to news